Sigyn Therapeutics Business Summary

Sigyn Therapeutics, Inc. (SIGY) is a development-stage biotechnology company specializing in the design and clinical advancement of multi-function blood purification technologies. The company’s business model is centered on the development of disposable, single-use medical devices—most notably Sigyn Therapy™ and the recently introduced CardioDialysis™—which are engineered to be deployed on the existing global infrastructure of hemodialysis and continuous renal replacement therapy (CRRT) machines. Sigyn generates value through the progression of its intellectual property toward regulatory clearance, with future revenue streams expected from product commercialization, strategic licensing, or asset sales. The company operates as a single business segment focused on treating life-threatening inflammatory conditions, such as sepsis and cytokine storm syndrome, as well as cardiovascular disease and oncology-related toxicities. Within the competitive landscape, Sigyn contends with players like Aethlon Medical, InspireMD, Inspira Technologies, and Avinger, distinguishing itself by targeting a broad spectrum of inflammatory targets and leveraging established clinical footprints to minimize adoption barriers. The leadership team is anchored by Co-Founder, Chairman, and CEO James "Jim" A. Joyce, a veteran executive with over 30 years of public market experience who previously founded Aethlon Medical and led it to a Nasdaq listing. Joyce is credited with overseeing the development of the Hemopurifier®, the first medical device cleared by the FDA to treat a pandemic virus. He is supported by Independent Director Jim Dorst, who brings over 30 years of financial management experience from roles at SYNNEX/Concentrix and Aethlon Medical, and Eric Lynam, who oversees clinical affairs following a career managing nearly 200 clinical trials at Pharmatech. The technical foundation is further bolstered by Craig P. Roberts, a key inventor of the IMPACT System and a percutaneous ECMO system later sold to C.R. Bard. Notable institutional backing includes Irrus Investments, reflecting the company’s strategic focus on high-impact therapeutic interventions.